

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

INSIDE INFORMATION
UPDATE ON LITIGATION

This announcement is made by China Health Group Limited (the “**Company**”), together with its subsidiaries, the “**Group**” pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the section titled “OTHER PAYABLES AND ACCRUED EXPENSES” in the interim results announcement dated 30 November 2023 (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company is pleased to update its shareholders and potential investors that, based on the judgment (the “**Judgment**”) for the 2549 & 2569 Action recently handed down by the Court on 20 December 2023, Capital Foresight’s claim against the Company for the US\$4 million promissory note is dismissed by the Court.

In dismissing Capital Foresight’s claim in HCA 2569/2017 for the US\$4 million promissory note, the Court accepted that a maturity date was not agreed and the absence of any agreement as to the maturity date of the promissory note to be issued is a flaw.

In relation to the Company’s claim in HCA 2549/2017, the Court considered that the Company failed to prove facts and matters which justify the court drawing inferences that the Capital Foresight Agreement, the Loan Note and the subsequent negotiation of agreements between the Company and Capital Foresight and Capital Foresight and the sole shareholder of Li Hong evidence the backdoor arrangement and the Court rejected the claims against all three Defendants.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Health Group Limited
Zhang Fan
Chairman of the Board and Executive Director

Hong Kong, 21 December 2023

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Zhang Fan (Chairman) and Mr. Chung Ho; three non-executive Directors, namely, Mr. Xing Yong, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.